Clinic business

Numinus’ Continued Collaboration with Health Canada Boosts Mindspace Clinic Approval in Quebec

A long-standing commitment of Numinus Wellness Inc. NUMBER collaborate with Health Canada help develop protocols for Special Access Program seems to be paying dividends. Last Monday, the company announced that its Montreal business mental space is about to become the first healthcare facility in Quebec to legally treat depression with psilocybin. Numinus CEO Payton Nyquvest sat down with TDR founder Shadd Dales to explain the significance of this milestone achievement.

Mindspace Clinic’s approval is the result of months of hard work and understanding of Health Canada’s requirements to move the approval process forward. Its genesis dates back to 2019, when Mindspace hosted one of the first training programs in Canada for clinicians wanting to learn more about how to help their clients work safely with psychedelics. Minspace then launched its Psychedelic Harm Reduction and Integration program and, in late 2020, began offering ketamine-assisted psychotherapy.

The acquisition of Mindspace by Numinus Wellness in February 2021 brought it closer to a company which itself has a strong reputation for working with Health Canada. Together, the Numinus-Mindspace entity has verifiably earned the trust of Canada’s leading government health authority to deliver experimental psilocybin-assisted therapy to people with treatment-resistant depression in Quebec. Ultimately, the green light demonstrates Health Canada’s deep confidence in Numinus’ ability to perform safe and effective treatments:

Shadd Dales: Why do you think that in the end, however, Health Canada granted you the opportunity to administer the first doses of this therapy in comparison to, say, other companies?

Payton Nyquvest: You know, we’ve built a long reputation with Health Canada, and we’ve been very collaborative in our approach. And really, you know, while — yes that’s newsworthy and yes that’s exciting — our focus has always been patient access and client access, and no, you know, how to generate the the most flashy press releases possible. And I think, you know, Health Canada is looking at this from a safety perspective and from the perspective of people in need of care… And I think Health Canada knows the rigor and the depth and the breadth that we take into regarding our clinical protocols, clinical operations – right down to what we do in the lab. So, you know, grateful—just very, very grateful that we can do the work that we do.

On January 5, 2022, Health Canada reinstated its Special Access Program– abolished under former Prime Minister Stephen Harper in 2013 – allowing healthcare experts to request access to restricted psychedelic drugs. Numinus is seeing a noticeable increase in the number of potential patients wanting to receive these treatments.

This article originally appeared on The Dales Report and appears here with permission.